The assay is designed to enable faster pathogen identification and susceptibility testing to guide UTI management.
News|Articles|October 1, 2025
Top 5 benign urology headlines you missed in September 2025
Fact checked by: Patrick Campbell
We recap notable headlines from last month in the benign urology space.
Advertisement
Advertisement
The month of September offered plenty of new research and expert insight in benign urological conditions. This included results from the RAPID I study evaluating the FloStent device for benign prostatic hyperplasia (BPH), a report on innovative stone-treating technology, an update to the American Urological Association/Canadian Urological Association/Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction guideline on recurrent uncomplicated urinary tract infections (uUTIs) in women, and more.
Related to this article
Early neurophysiology and pressure-flow research directly underpin modern urodynamics, whereas Turner-Warwick's restorative philosophy, according to Sasha Vereecken, BScN, RN.
These FAQs outline key recommendations and practical takeaways from the 2026 AUA Medical Management of Kidney Stones guideline amendment.
Jonathan Harper, MD, discusses findings from the PUSH trial may inform counseling on hydration and stone recurrence.
Cameron C. Jones, MD, discusses patient selection for Aquablation, including prostate size, anatomy, and factors that may favor alternative BPH procedures.
The Zenflow Spring Implant and Delivery System has entered commercial use for BPH following its FDA approval in December 2025.
Enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) showed the strongest EFS, OS, and PCR associations among neoadjuvant MIBC strategies in a network meta-analysis, although perioperative design limits attribution.
Sandip Prasad, MD, MPhil, discusses the evolving role of chemoablation in recurrent low-grade, intermediate-risk NMIBC, including patient selection and treatment considerations.
Advertisement
Advertisement